Tresiba® is a long-acting basal insulin indicated to improve glycemic control in patients 1 year of age and older with type 1 or type 2 diabetes.1
Broad formulary coverage
Have you checked the latest coverage for Tresiba®, including for your Medicare Part D patients?
Available in FlexTouch® U-100 or U-200
Patients converting from Levemir® will already be familiar with the pen mechanics. And unit dosing for Tresiba® remains the same, no matter which pen you prescribe.
See the results from the DEVOTE safety outcomes trial
See risk of major adverse cardiovascular events (MACE)a and rates and incidence of severe hypoglycemia for Tresiba® U-100 vs insulin glargine U-100 for adult patients with T2D and ASCVD.1,b
aASCVD=atherosclerotic cardiovascular disease; MACE=cardiovascular death, nonfatal MI, or nonfatal stroke; T2D=type 2 diabetes.
bSevere hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions and during which plasma glucose concentration may not have been available, but where neurological recovery following the return of plasma glucose to normal was considered sufficient evidence that the event was induced by a low plasma glucose concentration.1